Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B T Hennessy

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Minerva Ginecologica|September 17, 2005
Adjuvant therapy for breast cancerB T Hennessy, L Pusztai
The International Journal of Biochemistry & Cell Biology|May 10, 2006
Ovarian cancer: homeobox genes, autocrine/paracrine growth, and kinase signalingB T Hennessy, G B Mills
The Oncologist|May 30, 2003
Chemotherapy options for the elderly patient with advanced non-small cell lung cancerB T Hennessy, E O Hanrahan, O S Breathnach
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2012
Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancerM S N Mohd Sharial, J Crown, B T Hennessy
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 14, 2005
Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literatureB T Hennessy, A M Gauthier, L B Michaud, et al.
Breast Cancer Research and Treatment|December 28, 2014
HER2-family signalling mechanisms, clinical implications and targeting in breast cancerN Elster, D M Collins, S Toomey, et al.
Irish Journal of Medical Science|August 8, 2016
The impact of outpatient systemic anti-cancer treatment on patient costs and work practicesD C Collins, M Coghlan, B T Hennessy, et al.
Drugs of Today (Barcelona, Spain : 1998)|March 25, 2011
Quantitative proteomic analysis in breast cancerA Tabchy, B T Hennessy, A M Gonzalez-Angulo, et al.
Oncogene|November 8, 2011
Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrestP Russell, B T Hennessy, J Li, et al.
Breast Cancer Research and Treatment|December 22, 2014
A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinibN Elster, M Cremona, C Morgan, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Minerva Ginecologica|September 17, 2005
Adjuvant therapy for breast cancerB T Hennessy, L Pusztai
The International Journal of Biochemistry & Cell Biology|May 10, 2006
Ovarian cancer: homeobox genes, autocrine/paracrine growth, and kinase signalingB T Hennessy, G B Mills
The Oncologist|May 30, 2003
Chemotherapy options for the elderly patient with advanced non-small cell lung cancerB T Hennessy, E O Hanrahan, O S Breathnach
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2012
Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancerM S N Mohd Sharial, J Crown, B T Hennessy
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 14, 2005
Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literatureB T Hennessy, A M Gauthier, L B Michaud, et al.
Breast Cancer Research and Treatment|December 28, 2014
HER2-family signalling mechanisms, clinical implications and targeting in breast cancerN Elster, D M Collins, S Toomey, et al.
Irish Journal of Medical Science|August 8, 2016
The impact of outpatient systemic anti-cancer treatment on patient costs and work practicesD C Collins, M Coghlan, B T Hennessy, et al.
Drugs of Today (Barcelona, Spain : 1998)|March 25, 2011
Quantitative proteomic analysis in breast cancerA Tabchy, B T Hennessy, A M Gonzalez-Angulo, et al.
Oncogene|November 8, 2011
Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrestP Russell, B T Hennessy, J Li, et al.
Breast Cancer Research and Treatment|December 22, 2014
A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinibN Elster, M Cremona, C Morgan, et al.
Pageof 3